Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Johnson erupts over ‘dangerous’ Biden mental decline ‘cover-up,’...
House panel directs chairman to subpoena Bill and...
Trump declares US will win global AI race...
Pro-Israel Dem says those who won’t decry Hamas...
Senate Republicans call on DOJ to appoint special...
‘Shirts and Skins’: How one Republican bridged the...
House Republicans zero in on Biden autopen pardons...
DOJ forms Russiagate ‘strike force’ to investigate declassified...
Ex-Biden chief of staff Ron Klain arrives for...
Why Fetterman is right: The fight against cashless...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

HHS SEC ROBERT F KENNEDY JR: American patients pay more so others can pay less — that stops now

by admin May 17, 2025
May 17, 2025
HHS SEC ROBERT F KENNEDY JR: American patients pay more so others can pay less — that stops now
NEWYou can now listen to Fox News articles!

President Donald Trump’s bold executive order on drug pricing isn’t just policy—it’s a revolution in healthcare affordability. The plan is simple yet transformative: ensure Americans pay no more for medications than citizens of other wealthy nations.

Consider this stark reality: a GLP-1 drug costing $88 in London commands $1,000 in the United States. Even after manufacturer discounts to insurers, Americans still pay over $400—for the identical medication, from the same company, produced in the same facility. This disparity is especially galling when pharmaceutical companies extract 70% of their profits from America—a nation representing just 4% of the world’s population. This global free-riding on American patients ends now.

Industry leaders recognize this imbalance. I’ve already engaged with CEOs from four major American pharmaceutical companies and a foreign manufacturer eager to relocate to the U.S. Their response has been encouraging, but we’re prepared to act decisively if necessary. U.S. Health and Human Services and Centers for Medicare & Medicaid Services (CMS) possess the statutory authority to deliver on President Trump’s commitment: other developed nations must pay more, so Americans can pay less, thus preserving the innovation pipeline.

Americans deserve both groundbreaking therapies and affordable access to them. Yet according to the Kaiser Family Foundation, nearly one-third of patients skip prescribed medications due to cost—an unacceptable reality in the world’s wealthiest nation.

While prevention through healthier lifestyles remains our best strategy for reducing medication dependence, certain treatments will always be essential. The pharmaceutical industry has delivered remarkable advancements in cancer and autoimmune therapies that benefit patients worldwide. 

We value continued innovation as a core American principle, but we cannot indefinitely subsidize global medical progress while other wealthy nations contribute disproportionately little.

President Trump’s negotiation approach has already proven effective with NATO, where European countries responded to accountability by making historic reinvestments that strengthened the alliance. The same principle applies here. The President and I stand united: global free riding on American patients must end.

CMS, with Dr. Mehmet Oz at the helm, extends beyond payment reform to fundamentally realigning care delivery incentives. This initiative will protect safety nets for vulnerable populations while addressing the financial pressures facing state partners and federal programs—particularly Medicaid, which has seen dramatic growth in both enrollment and costs.

The coming months will be decisive in achieving President Trump’s prescription for a healthier America—one where innovation thrives, and patients no longer shoulder an unfair share of the global healthcare burden.

This post appeared first on FOX NEWS

previous post
Middle East trip highlights President Donald Trump’s 17th week in office
next post
Biden jokes ‘I’m a young man’ during interview with Special Counsel Robert Hur

You may also like

Kamala Harris vetting list of possible running mates...

July 26, 2024

House passes nearly $1 trillion defense spending bill,...

December 12, 2024

Harris claimed Biden was completely fit to continue...

July 29, 2024

Experts sound alarm on Biden’s offshore drilling ban...

January 15, 2025

MORNING GLORY: Don’t DOGE The Deadline! 

November 14, 2024

Biden, Trump both rip DOJ after president pardons...

December 3, 2024

Republicans raise alarm over US vulnerability to mass...

June 27, 2025

Mast demands VA fire staffers over Vance, Walz...

October 1, 2024

House witness flips script on Dem who ambushed...

June 8, 2025

DOGE boasts dozens of contract cancellations on Wednesday,...

February 13, 2025

Recent Posts

  • Johnson erupts over ‘dangerous’ Biden mental decline ‘cover-up,’ while Democrats push Epstein disclosure
  • House panel directs chairman to subpoena Bill and Hillary Clinton in Epstein probe
  • Trump declares US will win global AI race during executive order signing ceremony: ‘Whatever it takes’
  • Pro-Israel Dem says those who won’t decry Hamas over Oct. 7 attack ‘have no business’ posing as humanitarians
  • Senate Republicans call on DOJ to appoint special counsel in Obama-Russia investigation

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (835)
    • Investing (2,607)
    • Politics (3,216)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.